Bortezomib for the treatment of mantle cell lymphoma: an update - Wikidata - awgldk - TriplyDB

Bortezomib for the treatment of mantle cell lymphoma: an update

Bortezomib for the treatment of mantle cell lymphoma: an update

http://www.wikidata.org/entity/Q26738940

about

The hypoxia signalling pathway in haematological malignancies.MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation.BaxΔ2 sensitizes colorectal cancer cells to proteasome inhibitor-induced cell death.Targeting FBPase is an emerging novel approach for cancer therapy.

P2860

Q39246376-749E7FE5-172F-4087-AAC1-5C8EA918D602 Q41080887-B94200B1-2128-462B-A65E-878EC411F9F5 Q47240693-84CFC0CA-B608-4600-B74D-5451CDDE2F6C Q52647812-67BCF267-9BF2-4DFB-9AFB-7321F3B2D8FB

P2860

Bortezomib for the treatment of mantle cell lymphoma: an update

http://www.wikidata.org/entity/Q26738940

description

2016 nî lūn-bûn

@nan

2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Bortezomib for the treatment of mantle cell lymphoma: an update

@ast

Bortezomib for the treatment of mantle cell lymphoma: an update

@en

Bortezomib for the treatment of mantle cell lymphoma: an update

@nl

type

label

Bortezomib for the treatment of mantle cell lymphoma: an update

@ast

Bortezomib for the treatment of mantle cell lymphoma: an update

@en

Bortezomib for the treatment of mantle cell lymphoma: an update

@nl

prefLabel

Bortezomib for the treatment of mantle cell lymphoma: an update

@ast

Bortezomib for the treatment of mantle cell lymphoma: an update

@en

Bortezomib for the treatment of mantle cell lymphoma: an update

@nl

P1433

Q26738940-606748EE-1341-4F06-8CF7-E652F942BE5D

P1476

Q26738940-F4D51AEB-3EEF-497A-B42C-4CC18CBBF597

P2093

Q26738940-641F8810-0551-4EDA-BA3B-62CA783D0CB0

Q26738940-B3794D12-C076-4D07-9D0E-E7A9F01A0383

P2860

Q26738940-0EEFE3BF-E533-412E-81E3-721EB335E847

Q26738940-124FAEBC-66CE-4029-AFE1-5A050D705C15

Q26738940-14D6F98D-7E1E-4D46-993E-C9EEFDFFCB1C

Q26738940-189FAAB9-5671-4F5F-BBF5-EF39DF4A68E4

Q26738940-1F9B5E47-956A-4F24-8DFF-8B61EAD25C01

Q26738940-26BB0A25-F488-43DF-800A-67086C1C9F03

Q26738940-2B97386A-A9AE-44C2-A3CE-172381EF3735

Q26738940-3249304B-8163-484A-A2D2-AA120A1DCA55

Q26738940-36B85789-073D-4100-BB05-F50589E9A78B

Q26738940-3D9E5E44-F499-4EF8-9989-6BFB62D76B4E

P304

Q26738940-5B26D61D-444C-4C03-BED2-340D6666FAAD

P31

Q26738940-2861C846-D76E-4444-806D-4CC3DC7C1A82

P356

Q26738940-7F41AB51-730F-4735-8212-1CDBD52A8B57

P407

Q26738940-7A509E51-CE0D-43AA-A5E8-87D30E9DAFE1

P433

Q26738940-21CCDE41-413C-4FEA-BA62-89446643BEFA

P478

Q26738940-E57A3465-91B8-4A3D-8B09-C26A104F731A

P50

Q26738940-B7B4655E-0A33-4BCC-88C2-B70F4B7062B1

P577

Q26738940-559BF42D-2057-4453-B9ED-59297D316D83

P698

Q26738940-9A593FCA-26D5-4E59-B4BF-0696CA7228AF

P932

Q26738940-E98A31D2-25CF-420E-83BD-E73DEF433470

P356

2040620716648566

P1433

Therapeutic advances in hematology

P1476

Bortezomib for the treatment of mantle cell lymphoma: an update

@en

P2093

Basem M William

http://www.w3.org/2001/XMLSchema#string

Paolo F Caimi

http://www.w3.org/2001/XMLSchema#string

P2860

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Mantle cell lymphoma: observation to transplantation

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma

TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB

NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

P304

196-208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2040620716648566

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Bryan C Hambley

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27493710

http://www.w3.org/2001/XMLSchema#string

P932

4959639

http://www.w3.org/2001/XMLSchema#string